

Section 1: Issuer information	
Name of issuer	Promisia Healthcare Limited
NZX ticker code	PHL / PHLWA
Class of financial product	Ordinary Shares / Equity Warrants
ISIN (If unknown, check on NZX website)	NZPRPE0001S5 / NZPHLE0002S3
Currency	NZD
Section 2: Capital change details	
Number issued/ acquired / redeemed	Equity warrants in PHL (Warrants) redeemed on exercise: 130,000 Ordinary Shares in PHL (Shares) issued on exercise of Warrants: 130,000
Nominal value (if any)	N/A
Issue/ acquisition / redemption price per security	\$0.50
Nature of the payment (for example, cash or other consideration)	130,000 Shares were issued for cash on exercise of a corresponding number of Warrants.
Amount paid up (if not in full)	Fully paid
Percentage of total class of Financial Products issued/ acquired / redeemed / (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence) ¹	0.246% of Shares issued 0.459% of Warrants exercised
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	N/A
Reason for issue/ acquisition / redemption and specific authority for issue/ acquisition / redemption / (the reason for change must be identified here)	Shares were issued upon the exercise of Warrants in accordance with the terms of issue of the Warrants.
Total number of Financial Products of the Class after the issue/ acquisition / redemption /Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/ acquisition / redemption .	Shares: 52,949,550 Warrants: 28,220,000
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	N/A

¹ The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

Specific authority for the issue, acquisition, or redemption , including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	NZX Listing Rule 4.9.1(b).
Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)	Warrants converted into Shares in accordance with the Warrant Terms of Issue. Each Warrant can be exercised at any time before the expiry date, being 5pm 24 March 2027, at an exercise price of \$0.50 per Warrant. Each Warrant converts to one Share upon exercise. The Shares issued upon conversion of the Warrants are of the same class and terms as all other Shares.
Date of issue/ acquisition/redemption ²	7 August 2026
Section 4: Authority for this announcement and contact person	
Name of person authorised to make this announcement	Matt Yates
Contact person for this announcement	Matt Yates
Contact phone number	0212779350
Contact email address	matt.yates@duncancotterill.com
Date of release through MAP	7 August 2026

² Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).